Cadrenal Therape Financials
Financial Health Signals
Cadrenal Therape passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Cadrenal Therape generates $0.69 in operating cash flow (-$7.4M OCF vs -$10.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Cadrenal Therape (CVKD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Cadrenal Therape's EBITDA was -$11.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 43.6% from the prior year.
Cadrenal Therape generated -$7.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 108.4% from the prior year.
Cadrenal Therape reported -$10.7M in net income in fiscal year 2024. This represents a decrease of 27.5% from the prior year.
Cadrenal Therape earned $-8.73 per diluted share (EPS) in fiscal year 2024. This represents an increase of 6.0% from the prior year.
Cadrenal Therape held $10.0M in cash against $0 in long-term debt as of fiscal year 2024.
Cadrenal Therape paid $16.50 per share in dividends in fiscal year 2024.
Cadrenal Therape had 2M shares outstanding in fiscal year 2024. This represents an increase of 105.3% from the prior year.
Cadrenal Therape invested $4.2M in research and development in fiscal year 2024. This represents an increase of 3.0% from the prior year.
Cadrenal Therape invested $7K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 100.9% from the prior year.
CVKD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $688K-36.1% | $1.1M-35.4% | $1.7M+112.6% | $785K-37.4% | $1.3M+99.3% | $629K | N/A | $244K |
| SG&A Expenses | $2.0M-23.0% | $2.7M+17.8% | $2.3M+34.6% | $1.7M+38.1% | $1.2M+7.7% | $1.1M | N/A | $898K |
| Operating Income | -$2.7M+26.8% | -$3.7M+4.9% | -$3.9M-59.7% | -$2.5M+0.3% | -$2.5M-40.5% | -$1.8M | N/A | -$1.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.7M+26.8% | -$3.7M+4.6% | -$3.8M-59.7% | -$2.4M-0.6% | -$2.4M-43.9% | -$1.7M | N/A | -$1.0M |
| EPS (Diluted) | $-1.31+29.9% | $-1.87+10.5% | $-2.09+4.1% | $-2.18 | $-2.24-43.6% | $-1.56 | N/A | $-1.01 |
CVKD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.1M-31.6% | $6.0M-24.8% | $8.0M-21.4% | $10.1M+85.5% | $5.5M-22.6% | $7.0M-17.3% | $8.5M-8.5% | $9.3M |
| Current Assets | $4.1M-31.7% | $6.0M-24.8% | $7.9M-21.4% | $10.1M+85.8% | $5.4M-22.5% | $7.0M-17.2% | $8.5M-8.5% | $9.3M |
| Cash & Equivalents | $3.9M-30.7% | $5.6M-24.1% | $7.3M-26.8% | $10.0M+98.9% | $5.0M-23.3% | $6.6M-21.9% | $8.4M-7.8% | $9.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.4M-19.5% | $1.7M-8.7% | $1.8M-31.4% | $2.7M+83.2% | $1.5M+71.1% | $856K+3.6% | $827K+46.1% | $566K |
| Current Liabilities | $1.4M-19.5% | $1.7M-8.7% | $1.8M-31.4% | $2.7M+83.2% | $1.5M+71.1% | $856K+3.6% | $827K+46.7% | $564K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.7M-36.4% | $4.3M-29.7% | $6.1M-17.8% | $7.4M+86.4% | $4.0M-35.5% | $6.2M-19.5% | $7.7M-12.0% | $8.7M |
| Retained Earnings | -$35.9M-8.1% | -$33.2M-12.4% | -$29.6M-14.9% | -$25.7M-34.5% | -$19.1M-14.3% | -$16.7M-11.0% | -$15.1M-8.2% | -$13.9M |
CVKD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.4M+22.1% | -$3.0M+34.9% | -$4.6M-159.6% | -$1.8M-17.1% | -$1.5M+16.7% | -$1.8M-164.4% | -$694K-10.6% | -$628K |
| Capital Expenditures | $2K | $0-100.0% | $3K | N/A | N/A | N/A | $0-100.0% | $1 |
| Free Cash Flow | -$2.4M+22.0% | -$3.0M+35.0% | -$4.7M | N/A | N/A | N/A | -$694K-10.6% | -$628K |
| Investing Cash Flow | -$2K | $0+100.0% | -$3K | N/A | N/A | N/A | $0+100.0% | -$1 |
| Financing Cash Flow | $648K-48.6% | $1.3M-36.0% | $2.0M-73.6% | $7.5M | $0-100.0% | $298+102.4% | -$13K-100.2% | $6.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CVKD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -65.7%-4.4pp | -61.3%-13.0pp | -48.4%+3.1pp | -51.5%-7.6pp | -43.9%-20.3pp | -23.6% | N/A | -11.1% |
| Current Ratio | 3.02-0.5 | 3.56-0.8 | 4.32+0.5 | 3.77+0.1 | 3.72-4.5 | 8.21-2.1 | 10.27-6.2 | 16.46 |
| Debt-to-Equity | 0.49+0.1 | 0.39+0.1 | 0.30-0.1 | 0.360.0 | 0.37+0.2 | 0.14+0.0 | 0.11+0.0 | 0.06 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Cadrenal Therape profitable?
No, Cadrenal Therape (CVKD) reported a net income of -$10.7M in fiscal year 2024.
What is Cadrenal Therape's earnings per share (EPS)?
Cadrenal Therape (CVKD) reported diluted earnings per share of $-8.73 for fiscal year 2024. This represents a 6.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cadrenal Therape's EBITDA?
Cadrenal Therape (CVKD) had EBITDA of -$11.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Does Cadrenal Therape pay dividends?
Yes, Cadrenal Therape (CVKD) paid $16.50 per share in dividends during fiscal year 2024.
What is Cadrenal Therape's free cash flow?
Cadrenal Therape (CVKD) generated -$7.4M in free cash flow during fiscal year 2024. This represents a -108.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cadrenal Therape's operating cash flow?
Cadrenal Therape (CVKD) generated -$7.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cadrenal Therape's total assets?
Cadrenal Therape (CVKD) had $10.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cadrenal Therape's capital expenditures?
Cadrenal Therape (CVKD) invested $7K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cadrenal Therape spend on research and development?
Cadrenal Therape (CVKD) invested $4.2M in research and development during fiscal year 2024.
How many shares does Cadrenal Therape have outstanding?
Cadrenal Therape (CVKD) had 2M shares outstanding as of fiscal year 2024.
What is Cadrenal Therape's current ratio?
Cadrenal Therape (CVKD) had a current ratio of 3.77 as of fiscal year 2024, which is generally considered healthy.
What is Cadrenal Therape's debt-to-equity ratio?
Cadrenal Therape (CVKD) had a debt-to-equity ratio of 0.36 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cadrenal Therape's return on assets (ROA)?
Cadrenal Therape (CVKD) had a return on assets of -105.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cadrenal Therape's cash runway?
Based on fiscal year 2024 data, Cadrenal Therape (CVKD) had $10.0M in cash against an annual operating cash burn of $7.4M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cadrenal Therape's Piotroski F-Score?
Cadrenal Therape (CVKD) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cadrenal Therape's earnings high quality?
Cadrenal Therape (CVKD) has an earnings quality ratio of 0.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.